Literature DB >> 1918655

Fluoxetine vs. clomipramine in depressed patients: a controlled multicentre trial.

R Noguera1, R Altuna, E Alvarez, J L Ayuso, L Casais, C Udina.   

Abstract

A sample of 120 patients, all of whom met DSM-III criteria for major unipolar depressive disorder, were randomly allocated to two treatment groups. Sixty patients were treated with fluoxetine and 60 with clomipramine during a 6-week period. No significant difference was found in antidepressant efficacy, with improvement occurring on both drugs. Important differences were found in the side-effects profile of each group, their incidence being significantly lower and tending to disappear during the course of treatment in the group of patients treated with fluoxetine.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1918655     DOI: 10.1016/0165-0327(91)90045-t

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  5 in total

1.  Does study design influence outcome?. The effects of placebo control and treatment duration in antidepressant trials.

Authors:  Bret R Rutherford; Joel R Sneed; Steven P Roose
Journal:  Psychother Psychosom       Date:  2009-03-24       Impact factor: 17.659

2.  Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis.

Authors:  E Trindade; D Menon; L A Topfer; C Coloma
Journal:  CMAJ       Date:  1998-11-17       Impact factor: 8.262

3.  Effective and acceptable treatment for depression.

Authors:  J Nakielny
Journal:  BMJ       Date:  1993-04-24

Review 4.  Fluoxetine versus other types of pharmacotherapy for depression.

Authors:  A Cipriani; P Brambilla; T Furukawa; J Geddes; M Gregis; M Hotopf; L Malvini; C Barbui
Journal:  Cochrane Database Syst Rev       Date:  2005-10-19

5.  Less is more in antidepressant clinical trials: a meta-analysis of the effect of visit frequency on treatment response and dropout.

Authors:  Bret R Rutherford; Timothy M Cooper; Amanda Persaud; Patrick J Brown; Joel R Sneed; Steven P Roose
Journal:  J Clin Psychiatry       Date:  2013-07       Impact factor: 4.384

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.